Kosumi K, et al. - Among 1,708 individuals, researchers examined the relation of tumor PTGS2 (COX-2) expression with colorectal cancer mortality in BRAF-mutated tumors vs BRAF-wild-type tumors. They observed a stronger association between tumor PTGS2 (COX-2) expression and colorectal cancer mortality in BRAF-mutated tumors vs BRAF-wild-type tumors, where poor prognosis was linked with PTGS2 (COX-2) expression. It supported the interactive roles of PTGS2 (COX-2) expression and BRAF mutation status in prediction of individuals with colorectal cancer. The prognostic impact of PTGS2 (COX-2) expression varies based on BRAF mutation status.